Research Article Examining the Influence of Amniotic Fluid on Experimentally Induced Testicular Injury Due to Cisplatin Chemotherapy in a Rodent Model

Background and Objective: Cisplatin (CP), also known as cis-diamminedichloroplatinum (II), is a highly effective chemotherapeutic agent utilized in treating various malignancies, including those of the lung, uterus, rectum and testis. Due to its severe side effects associated with clinical use, CP's administration requires cautious evaluation. Testicular toxicity and injury are among the adverse consequences of CP treatment. The primary objective of this research was to explore the potential protective capabilities of AmnioMax (AMX) against CP-induced testicular damage by examining sperm parameters, testicular tissue alterations and oxidative/antioxidative markers within the rat testes. Materials and Methods: With 11 rats in each of the five groups (control, AMX, CP, CP+AMX and AMX+CP), there were 55 male Wistar albino rats utilized in the study. To assess oxidative stress, oxidative stress index (OSI) and total oxidant status (TOS) were determined, while total antioxidant status (TAS) was used to calculate for the antioxidant defense system in both tissue and blood specimens. The histology of the testicular tubules was evaluated using the Johnsen testicular biopsy score. A p-value of 0.05 or below was considered statistically significant. Results: This study investigated the potential protective effect of amniotic fluid on testicular injury induced by cisplatin chemotherapy in a rodent model. Biochemical assessment revealed a significant increase in total testis protein levels and mitochondrial IDH in the CP+AMX group compared to the CP group. Sperm analysis showed a significant improvement in sperm motility and viability in the CP+AMX group compared to the CP group. Histopathological examination demonstrated a significant reduction in fibrosis and a significant increase in JTBS in the CP+AMX and AMX+CP groups compared to the CP group. Overall, these findings suggest that amniotic fluid may have a protective effect against cisplatin-induced testicular injury. Conclusion: When compared in terms of whether the AMX injection should be administered before or after CP, the CP+AMX group had higher TAS levels and higher IDH levels, sperm viability and motility and Johnsen testis biopsy score compared to the AMX+CP group. Considering this, it can be concluded that the administration of AMX after CP is more appropriate.

Automated summary

This study aimed to investigate the potential protective effect of AmnioMax (AMX) against testicular injury induced by cisplatin (CP) chemotherapy. Results showed that the CP+AMX group had significantly increased levels of total testis protein and mitochondrial IDH in the testicular tissue, as well as improved sperm motility and viability, reduced fibrosis, and increased Johnsen testis biopsy score compared to the CP group. Overall, these findings suggest that amniotic fluid may have a protective effect against cisplatin-induced testicular injury.